US Advises Seniors Against Getting Chikungunya Vaccine Due to Safety Concerns
US health officials advise travelers aged 60 and above to avoid the chikungunya vaccine amid ongoing safety investigations due to potential side effects in older adults.
In recent health developments, US health authorities have issued a cautionary message to travelers aged 60 and above, recommending against receiving the chikungunya vaccine while investigations into potential side effects are ongoing. The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) released notices last week concerning the vaccine, Valneva's Ixchiq, which was previously recommended for adults traveling to regions affected by chikungunya.
Chikungunya is a mosquito-borne illness endemic to tropical areas, characterized by high fever, severe joint pain, and fatigue. Despite its typically mild initial symptoms, the disease can cause prolonged joint issues and significant health problems. Annually, around 100 to 200 cases are reported in the United States among travelers returning from affected regions.
The vaccine, developed using a weakened form of the chikungunya virus, was introduced last year as a preventive measure for at-risk populations. However, recent reports have raised safety concerns, particularly regarding older adults. A review by vaccine experts revealed six cases of individuals aged 65 and above who experienced heart or brain-related symptoms shortly after vaccination. Notably, most of these individuals had preexisting health conditions. Additional similar cases have been documented internationally.
Regulatory agencies in Europe are also examining these cases as part of their review process. In response to the emerging data, US advisory panels have recommended placing a precaution on the vaccine’s use in seniors over 65. Meanwhile, another chikungunya vaccine by Bavarian Nordic, Vimkunya, remains recommended for travelers aged 12 and older, though decisions on its widespread use are yet to be finalized.
This development underscores the importance of carefully evaluating vaccine safety, especially in vulnerable populations. Travelers are advised to consult healthcare providers for personalized recommendations and remain informed about ongoing safety assessments regarding chikungunya vaccination.
Source: https://medicalxpress.com/news/2025-05-health-older-chikungunya-vaccine.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Increasing Staff Levels in Aged Care: Does More Staffing Improve Care Quality?
While increased staffing levels in aged care homes meet targets, recent research questions whether it truly improves care quality. A nuanced approach focusing on workforce skills and support is crucial for better outcomes.
Empagliflozin Provides Kidney Protection and Heart Failure Risk Reduction in Acute Myocardial Infarction Patients
Empagliflozin shows promise in protecting kidney function and reducing heart failure risk in patients after acute myocardial infarction, according to recent research.
Wastewater Surveillance as a Reliable Predictor of COVID-19 Community Infections
A University of Minnesota study confirms that wastewater testing for SARS-CoV-2 accurately predicts upcoming COVID-19 case surges, supporting proactive public health responses.
Understanding Gait Differences in Autistic People
Autistic individuals often exhibit distinct gait patterns, including toe-walking and wider steps. These differences are linked to brain development and can impact daily activities. Understanding and supporting these motor variations are crucial for enhancing quality of life.